MUC16 and pancreatic intraductal papillary-mucinous neoplasm: In this study, two marker panels of CA19-9 and CA-125 or HE4 and CEA were demonstrated to be clinically useful to separate IPMN from PDAC as well as early stage PDAC or CP.